| 8.61 0.02 (0.23%) | 09-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Y-mAbs Therapeutics, Inc. is a biopharmaceutical firm already generating revenue, dedicated to discovering, advancing, and selling innovative antibody-derived therapies specifically designed to combat cancer within the United States. Its flagship product, DANYELZA, is a monoclonal antibody administered alongside granulocyte-macrophage colony-stimulating factor, targeting high-risk neuroblastoma in children when the disease has returned or proven resistant to prior treatments. Beyond its approved indication, DANYELZA is undergoing Phase II trials for new applications, including initial and third-line neuroblastoma, as well as relapsed osteosarcoma. Furthermore, Y-mAbs is progressing with a GD2-GD3 vaccine, currently in Phase II for aggressive Stage 4 neuroblastoma. Another key asset, Omburtamab, a murine monoclonal antibody, is being evaluated in clinical studies for a range of challenging conditions: central nervous system and leptomeningeal spread of neuroblastoma, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other cancers expressing the B7-H3 protein. The company's pipeline also features Nivatrotamab, which is being investigated for small cell lung cancer and is in Phase I/II trials for persistent GD2-positive solid tumors in both adult and pediatric populations. Completing its early-stage portfolio is Lu-omburtamab-DTPA, a Phase I candidate aimed at treating medulloblastoma and B7-H3 positive leptomeningeal metastases originating from solid tumors. Y-mAbs maintains a licensing arrangement with both the Memorial Sloan Kettering Cancer Center and the Massachusetts Institute of Technology, enabling it to advance and market certain agreed-upon therapies. Established in 2015, Y-mAbs Therapeutics, Inc. operates from its headquarters in New York City.
Tue, 16 Sep 2025
SERB Pharmaceuticals Completes Acquisition of Y-mAbs Therapeutics - Yahoo Finance
Wed, 13 Aug 2025
Acquisition Deal Triggers Weekly Surge for Y-mAbs Therapeutics Stock - Yahoo Finance
Thu, 07 Aug 2025
Mayer Brown advises the group Serb Pharmaceuticals on the structuring of the take-private of Y-mAb Therapeutics Inc. - Mayer Brown
Tue, 05 Aug 2025
SERB Pharmaceuticals To Acquire Y-mAbs Therapeutics - citybiz
Thu, 14 Mar 2024
Y-mAbs Therapeutics CFO Bo Kruse to Retire - citybiz
Wed, 18 Oct 2023
Y-mAbs Names Michael Rossi as CEO - citybiz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|